View Financial HealthCogstate 배당 및 자사주 매입배당 기준 점검 0/6Cogstate 은(는) 현재 수익률이 0.69% 인 배당금 지급 회사입니다.핵심 정보0.7%배당 수익률0.7%자사주 매입 수익률총 주주 수익률1.4%미래 배당 수익률2.0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향21%최근 배당 및 자사주 매입 업데이트공시 • Aug 23Cogstate Limited announces Annual dividend, payable on September 29, 2025Cogstate Limited announced Annual dividend of AUD 0.0200 per share payable on September 29, 2025, ex-date on August 27, 2025 and record date on August 28, 2025.모든 업데이트 보기Recent updates공시 • Jan 22Cogstate Limited Revises Earnings Guidance for the First Half Year Ended 31 December 2025Cogstate Limited revised earnings guidance for the first half year ended 31 December 2025. Total revenue $26.9 million, up 12% compared to previous corresponding period and above guidance of $25 million - $26 million.공시 • Jan 13Cogstate Limited to Report First Half, 2026 Results on Feb 19, 2026Cogstate Limited announced that they will report first half, 2026 results on Feb 19, 2026공시 • Aug 23Cogstate Limited announces Annual dividend, payable on September 29, 2025Cogstate Limited announced Annual dividend of AUD 0.0200 per share payable on September 29, 2025, ex-date on August 27, 2025 and record date on August 28, 2025.공시 • Aug 05Cogstate Limited, Annual General Meeting, Oct 16, 2025Cogstate Limited, Annual General Meeting, Oct 16, 2025.공시 • Jun 26Cogstate Limited Provides Earnings Guidance for the Second Half and Full Year Ending June 30, 2025Cogstate Limited provided earnings guidance for the second half and full year ending June 30, 2025. For the second half, the company expects revenues to be in the range of $28.1 million to $30.1 million, representing a material improvement on the first half of FY25. For the Full year, the company expects revenue is anticipated to be between $52 million and $54 million - an improvement of 20% to 24% on the prior year.공시 • May 29Cogstate Limited to Report Fiscal Year 2025 Results on Aug 22, 2025Cogstate Limited announced that they will report fiscal year 2025 results on Aug 22, 2025공시 • Jan 20Cogstate Limited to Report First Half, 2025 Results on Feb 20, 2025Cogstate Limited announced that they will report first half, 2025 results on Feb 20, 2025공시 • Oct 14Cogstate Appoints Kaycee Sink as Chief Medical OfficerCogstate announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies. Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial design decisions, endpoint selection, and data quality considerations for cognitive and clinical outcome assessments. Dr. Sink will also play a critical role in Cogstate’s efforts to commercialize cognitive assessment technologies within the community to support timely and more accurate diagnoses in healthcare. Dr. Sink joins Cogstate from Genentech (part of the Roche group of companies) where she was Principal Medical Director in Neurodegeneration, having leadership roles in the late-stage development of several molecules being studied for Alzheimer’s disease and other neurodegenerative disorders as well as digital applications for the same. She joined Genentech in 2017 after 13 years on faculty at Wake Forest School of Medicine, where she rose to tenured Full Professor of Medicine, Neurology, and Public Health Sciences. Dr. Sink is board certified in Internal Medicine and Geriatric Medicine with over 20 years of experience in clinical care and research in aging, Alzheimer’s disease, and other neurodegenerative disorders. She obtained her medical degree at the University of CA, San Francisco, and subsequently trained in internal medicine followed by clinical and research fellowships in geriatrics, also at UCSF. Dr. Sink continues to see patients and teach in the Memory Assessment Clinic as adjunct faculty at Wake Forest School of Medicine in Winston Salem, NC.공시 • Aug 24Cogstate Limited Provides Financial Guidance for the Fiscal Year 2025Cogstate Limited provided financial guidance for the fiscal year 2025. The company expects to grow revenue and profit in fiscal year 2025.공시 • Jan 15+ 2 more updatesCogstate Limited to Report First Half, 2024 Results on Feb 22, 2024Cogstate Limited announced that they will report first half, 2024 results on Feb 22, 2024공시 • Aug 23Cogstate Limited Provides Revenue Guidance for 2024Cogstate Limited provided revenue guidance for 2024. For the period, the company expects to grow revenue and profit.공시 • May 11Cogstate Limited Provides Revenue Guidance in the Fourth Quarter 2023Cogstate Limited provided earnings guidance for the he full year ended 30 June 2023. For the year, the company expects revenue to be in the range of $39 million - $41 million (9% - 12% below FY22); EBIT, from normal operations, is expected to be in the range of $1.0 million - $2.0 million; Net Profit before Tax, including restructure costs and interest revenue, is expected to be in the range of $0.6 million - $1.6 million.공시 • Feb 01+ 2 more updatesCogstate Limited to Report Fiscal Year 2023 Results on Aug 17, 2023Cogstate Limited announced that they will report fiscal year 2023 results on Aug 17, 2023공시 • Jan 25Cogstate Limited Announces Resignation of David Dolby as Non-Executive DirectorCogstate Limited advised that Mr. David Dolby has resigned as a non-executive director of Cogstate Ltd.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: COGZ.F US 시장에서 주목할만한 배당금을 지급하지 않으므로 지급이 안정적인지 확인할 필요가 없습니다.배당금 증가: COGZ.F US 시장에서 주목할만한 배당금을 지급하지 않으므로 지급액이 증가하는지 확인할 필요가 없습니다.배당 수익률 vs 시장Cogstate 배당 수익률 vs 시장COGZ.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (COGZ.F)0.7%시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Healthcare Services)1.3%분석가 예측 (COGZ.F) (최대 3년)2.0%주목할만한 배당금: COGZ.F 의 배당금( 0.69% )은 US 시장에서 배당금 지급자의 하위 25%( 1.41% )와 비교해 주목할 만하지 않습니다.고배당: COGZ.F 의 배당금( 0.69% )은 US 시장에서 배당금 지급자의 상위 25%( 4.24% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: COGZ.F US 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: COGZ.F US 시장에서 주목할만한 배당금을 지급하지 않습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 21:28종가2026/05/22 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cogstate Limited는 5명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Thomas WakimBell PotterElyse ShapiroCanaccord GenuityMadeleine WilliamsCanaccord Genuity2명의 분석가 더 보기
공시 • Aug 23Cogstate Limited announces Annual dividend, payable on September 29, 2025Cogstate Limited announced Annual dividend of AUD 0.0200 per share payable on September 29, 2025, ex-date on August 27, 2025 and record date on August 28, 2025.
공시 • Jan 22Cogstate Limited Revises Earnings Guidance for the First Half Year Ended 31 December 2025Cogstate Limited revised earnings guidance for the first half year ended 31 December 2025. Total revenue $26.9 million, up 12% compared to previous corresponding period and above guidance of $25 million - $26 million.
공시 • Jan 13Cogstate Limited to Report First Half, 2026 Results on Feb 19, 2026Cogstate Limited announced that they will report first half, 2026 results on Feb 19, 2026
공시 • Aug 23Cogstate Limited announces Annual dividend, payable on September 29, 2025Cogstate Limited announced Annual dividend of AUD 0.0200 per share payable on September 29, 2025, ex-date on August 27, 2025 and record date on August 28, 2025.
공시 • Aug 05Cogstate Limited, Annual General Meeting, Oct 16, 2025Cogstate Limited, Annual General Meeting, Oct 16, 2025.
공시 • Jun 26Cogstate Limited Provides Earnings Guidance for the Second Half and Full Year Ending June 30, 2025Cogstate Limited provided earnings guidance for the second half and full year ending June 30, 2025. For the second half, the company expects revenues to be in the range of $28.1 million to $30.1 million, representing a material improvement on the first half of FY25. For the Full year, the company expects revenue is anticipated to be between $52 million and $54 million - an improvement of 20% to 24% on the prior year.
공시 • May 29Cogstate Limited to Report Fiscal Year 2025 Results on Aug 22, 2025Cogstate Limited announced that they will report fiscal year 2025 results on Aug 22, 2025
공시 • Jan 20Cogstate Limited to Report First Half, 2025 Results on Feb 20, 2025Cogstate Limited announced that they will report first half, 2025 results on Feb 20, 2025
공시 • Oct 14Cogstate Appoints Kaycee Sink as Chief Medical OfficerCogstate announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies. Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial design decisions, endpoint selection, and data quality considerations for cognitive and clinical outcome assessments. Dr. Sink will also play a critical role in Cogstate’s efforts to commercialize cognitive assessment technologies within the community to support timely and more accurate diagnoses in healthcare. Dr. Sink joins Cogstate from Genentech (part of the Roche group of companies) where she was Principal Medical Director in Neurodegeneration, having leadership roles in the late-stage development of several molecules being studied for Alzheimer’s disease and other neurodegenerative disorders as well as digital applications for the same. She joined Genentech in 2017 after 13 years on faculty at Wake Forest School of Medicine, where she rose to tenured Full Professor of Medicine, Neurology, and Public Health Sciences. Dr. Sink is board certified in Internal Medicine and Geriatric Medicine with over 20 years of experience in clinical care and research in aging, Alzheimer’s disease, and other neurodegenerative disorders. She obtained her medical degree at the University of CA, San Francisco, and subsequently trained in internal medicine followed by clinical and research fellowships in geriatrics, also at UCSF. Dr. Sink continues to see patients and teach in the Memory Assessment Clinic as adjunct faculty at Wake Forest School of Medicine in Winston Salem, NC.
공시 • Aug 24Cogstate Limited Provides Financial Guidance for the Fiscal Year 2025Cogstate Limited provided financial guidance for the fiscal year 2025. The company expects to grow revenue and profit in fiscal year 2025.
공시 • Jan 15+ 2 more updatesCogstate Limited to Report First Half, 2024 Results on Feb 22, 2024Cogstate Limited announced that they will report first half, 2024 results on Feb 22, 2024
공시 • Aug 23Cogstate Limited Provides Revenue Guidance for 2024Cogstate Limited provided revenue guidance for 2024. For the period, the company expects to grow revenue and profit.
공시 • May 11Cogstate Limited Provides Revenue Guidance in the Fourth Quarter 2023Cogstate Limited provided earnings guidance for the he full year ended 30 June 2023. For the year, the company expects revenue to be in the range of $39 million - $41 million (9% - 12% below FY22); EBIT, from normal operations, is expected to be in the range of $1.0 million - $2.0 million; Net Profit before Tax, including restructure costs and interest revenue, is expected to be in the range of $0.6 million - $1.6 million.
공시 • Feb 01+ 2 more updatesCogstate Limited to Report Fiscal Year 2023 Results on Aug 17, 2023Cogstate Limited announced that they will report fiscal year 2023 results on Aug 17, 2023
공시 • Jan 25Cogstate Limited Announces Resignation of David Dolby as Non-Executive DirectorCogstate Limited advised that Mr. David Dolby has resigned as a non-executive director of Cogstate Ltd.